Navigation Links
Current Severe Outbreaks of Foot and Mouth Disease Predicted by Replikins' BioRadar(TM) One Year in Advance (June 2009)
Date:7/16/2010

LONDON, July 16 /PRNewswire/ -- BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.

The Foot and Mouth Disease outbreaks now rampant in Asia are moving west to the Middle East and south to Africa. The last major FMD outbreak followed the same path of spread, and cost approximately 17 billion pounds sterling when it reached the U.K. in 2001.

BioRadar(TM) also gave warning one year in advance (January 2009, ref. 2) of the re-emergence of H5N1 (bird) influenza. H5N1 is now producing outbreaks in chickens in 63 countries. In Egypt, H5N1 has appeared in 31 human cases (40% mortality). The accuracy of these predictions is supported by the fact that BioRadar(TM) predicted, one year in advance, the H1N1 pandemic of 2009.

Dr. Samuel Bogoch, chairman of BioRadar UK Ltd., reported to the Amsterdam conference that the new technology gives accurate advance notice of virus outbreaks.

Further, two Replikins synthetic vaccines have been found by others to be effective against H5N1 influenza in chickens (TransFlu(TM)) (ref. 3) and against lethal Taura Syndrome virus in shrimp. These synthetic non-biological methods produce Replikins vaccines in 7 days rather than the six to eight months required by older biological methods. Regardless of which method of vaccine production is used, even using standard biological methods, one year of additional time to produce and test vaccines is now possible.

United Kingdom's UK Trade and Investment (UKTI) announced that BioRadar UK Ltd. has "one of the first reliable systems for accurately predicting the strain of future flu outbreaks together with the severity and duration." Subscriptions to the Replikins BioRadar Global Surveillance System(TM) are being received by BioRadar UK Ltd.

Contact: John McKenney, jMckenney@replikins.com, 617-536-0220

References:

1. Bogoch S. and Bogoch ES. Replikins: the chemistry of rapid replication. Begell House, N.Y. 2005. Library of Congress.  

2. Website: http://replikins.com, Replikins Press - 35 online reports, 2006-2010.

3. Jackwood, M. et al. Efficacy of a Replikin Peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus. doi: 2009.10.637/8892-042509; full paper in Avian Diseases 2009.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
2. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
3. The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer
4. Penn material scientists turn light into electrical current using a golden nanoscale system
5. Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy
6. New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents
7. Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future Pipeline
8. Enobia Raises US$50M from Current Investors in Series C Financing
9. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
10. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
11. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):